Whether you are targeting a protein-protein interaction, developing an agonist, antagonist, or delivery agent, we’ll use our broad scientific expertise in phage display to drive your project from phage library screening and affinity selection, through characterization, and development.
Our high-complexity phage display libraries, each containing more than a billion peptide variants, are available in both linear and Cys-constrained formats. These libraries facilitate the identification of peptides with exceptional affinity and specificity for various targets.
Through iterative rounds of affinity selection and screening, we isolate peptides that exhibit high specificity and affinity for your targets. Our phage display library screening process is tailored to meet the unique requirements of each project.
We offer a comprehensive range of modification strategies and analytical tools to ensure your peptides are optimized for therapeutic applications. Our services include peptide synthesis, characterization of affinity and specificity, chemical SAR, and modifications to enhance in vivo stability.
Discover how IRBM’s advanced phage display library services accelerate peptide drug discovery. In this exclusive excerpt, Claudia Dall’Armi explains how our proprietary display technologies identify high-affinity peptide leads, leveraging over 20 years of expertise and an extensive collection of unique phage libraries.
MODIFICATION STRATEGIES & ANALYTICAL TOOLS
- In-house libraries, each with > 109 complexity:
- Linear and Cys-constrained random or conformational peptide libraries on M13 pVIII- and pIII-display formats
- Selection and screening strategy based on specific project requirements
- Recombinant proteins, on cells, in vivo
- Screening by single clone analysis and/or NGS
- Binding and/or functional assays
- Peptide synthesis and characterization of affinity, specificity, activity
- Chemical SAR and modification to gain in vivo stability
- DMPK
Contact us today to learn how our phage display library services can accelerate your peptide drug discovery efforts.
Relevant Publications on this Topic
March 01 2025De novo discovery of cyclic peptide inhibitors of IL-11 signalingUnlocking New Avenues for IL-11 Therapeutics Interleukin-11 (IL-11), a member of the cytokine family, has…READ MORE
Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library.Demartis A, Lahm A, Tomei L, Beghetto E, Di Biasio V, Orvieto F, Frattolillo F, Carrington PE, Mumick S, Hawes…READ MORE
Whole-Genome Phage Display Libraries: A Powerful Tool for Antigen DiscoveryBeghetto E, Gargano N. Whole-Genome Phage Display Libraries: A Powerful Tool for Antigen Discovery. Methods Mol Biol. 2019;2024:181-198. doi: 10.1007/978-1-4939-9597-4_11…READ MORE
In this work, we highlight how IRBM leverages Surface Plasmon Resonance (SPR) technology as a crucial part of the screening process for therapeutic peptides and monoclonal antibodies.
Start a conversation.
Great science begins here.